E E Voest
Overview
Explore the profile of E E Voest including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
1994
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verkerk K, Zeverijn L, van de Haar J, Roepman P, Geurts B, Spiekman A, et al.
ESMO Open
. 2025 Jan;
10(1):104112.
PMID: 39778224
Background: Many patients with cancer exhibit primary or rapid secondary resistance to targeted therapy (TT). We hypothesized that a higher number of altered oncogenic signaling pathways [pathway alteration load (PAL)]...
2.
Verkerk K, Voest E
Cell
. 2024 Mar;
187(7):1636-1650.
PMID: 38552611
The precision oncology paradigm challenges the feasibility and data generalizability of traditional clinical trials. Consequently, an unmet need exists for practical approaches to test many subgroups, evaluate real-world drug value,...
3.
Mulder J, Teerenstra S, van Hennik P, Pasmooij A, Stoyanova-Beninska V, Voest E, et al.
ESMO Open
. 2023 Apr;
8(2):101209.
PMID: 37054504
Background: Single-arm trials (SATs) can sometimes be used to support marketing authorization of anticancer medicinal products in the European Union. The level and durability of antitumor activity of the product...
4.
Schipper L, Samsom K, Snaebjornsson P, Battaglia T, Bosch L, Lalezari F, et al.
ESMO Open
. 2022 Dec;
7(6):100611.
PMID: 36463731
Background: In ∼3%-5% of patients with metastatic disease, tumor origin remains unknown despite modern imaging techniques and extensive pathology work-up. With long diagnostic delays and limited and ineffective therapy options,...
5.
van Berge Henegouwen J, Jebbink M, Hoes L, van der Wijngaart H, Zeverijn L, van der Velden D, et al.
Eur J Cancer
. 2022 Jun;
171:114-123.
PMID: 35716537
Introduction: In 1-3% of non-small cell lung cancer (NSCLC) human epidermal growth factor 2 (HER2) mutations are identified as a genomic driver. Nevertheless, no HER2-targeted treatment is approved for NSCLC....
6.
van Berge Henegouwen J, van der Wijngaart H, Zeverijn L, Hoes L, Meertens M, Huitema A, et al.
Cancer Chemother Pharmacol
. 2022 May;
90(1):97-104.
PMID: 35598186
Introduction: The combination of vemurafenib, a proto-oncogene B-Raf inhibitor (BRAFi) and cobimetinib, an inhibitor of mitogen-activated protein kinase kinase (MEKi) has shown to improve survival in patients with BRAF V600-mutated...
7.
Ooft S, Weeber F, Schipper L, Dijkstra K, McLean C, Kaing S, et al.
ESMO Open
. 2021 Apr;
6(3):100103.
PMID: 33887686
Background: Organoid technology has recently emerged as a powerful tool to assess drug sensitivity of individual patient tumors in vitro. Organoids may therefore represent a new avenue for precision medicine,...
8.
de Vries E, Cherny N, Voest E
Ann Oncol
. 2020 Jan;
30(12):2018.
PMID: 31893487
No abstract available.
9.
de Vries E, Cherny N, Voest E
Ann Oncol
. 2019 Nov;
30(10):1536-1538.
PMID: 31688929
No abstract available.
10.
van der Velden D, Hoes L, van der Wijngaart H, van Berge Henegouwen J, van Werkhoven E, Roepman P, et al.
Nature
. 2019 Oct;
574(7776):127-131.
PMID: 31570881
The large-scale genetic profiling of tumours can identify potentially actionable molecular variants for which approved anticancer drugs are available. However, when patients with such variants are treated with drugs outside...